Assessing Immunovant (IMVT) Valuation After Strong IMVT-1402 Data And Refocused Pipeline Strategy Simply Wall St 13:26 Thu, 21 May
Immunovant rises on Imvt-1402 data in difficult-to-treat Ra BioWorld 22:03 Wed, 20 May Article paywall
Roivant Sciences Shares Jump 14.43% to $32.28 on Strong IMVT-1402 Rheumatoid Arthritis Data International Business Times - AU Edition 16:07 Wed, 20 May
Immunovant Shares Surge 31.86% to $34.67 on Positive IMVT-1402 Rheumatoid Arthritis Data International Business Times - AU Edition 15:47 Wed, 20 May
